Isolated biotin-resistant 3-methylcrotonyl-CoA carboxylase deficiency: long-term outcome in a case with neonatal onset.
A patient with early-onset 3-methylcrotonyl coenzyme A carboxylase (MCC) deficiency showing a severe clinical course is described. Abnormal eye and head movements suggestive of seizures were noticed soon after birth. Tonic convulsions at the age of 10 weeks led to admission. Urinary organic acid analysis using gas chromatography-mass spectrometry at 3 months of age revealed elevated concentrations of 3-hydroxyisovaleric acid (3HIVA) and 3-methylcrotonylglycine but normal levels of lactate, 3-hydroxypropionate and methylcitrate suggesting isolated MCC deficiency. This was confirmed by enzyme assays in lymphocytes and cultured skin fibroblasts: MCC activity was virtually undetectable whereas activities of propionyl-CoA and pyruvate carboxylases were within the normal range. A low protein (0.8-1.5 g/kg/day) diet supplemented with a leucine-free amino acid mixture resulted in a marked decrease of 3HIVA excretion. L-Carnitine and biotin administration had no effect on the clinical condition or metabolite excretion. Supplementation with glycine resulted in only a temporary fall of 3HIVA excretion and was therefore discontinued. L-Carnitine therapy was reintroduced later because of secondary carnitine deficiency. Compliance with treatment was poor until the age of 27 months resulting in a severe episode with seizures and coma. The general clinical condition of the patient was always good but his psychomotor development was delayed and seizures were not continuously under good control due to poor therapy compliance. The boy is now 10.5 years old and attending a school for children with learning handicaps.


CONCLUSIONS
Isolated MCC deficiency of early-onset is a rare condition exhibiting a more severe clinical course than the later-onset form described in most other cases. The prognostic value of 3 HIVA measurements in CSF and serum should be evaluated in future cases.
Lehnert
W
W
University Children's Hospital, Freiburg, Germany.
Niederhoff
H
H
Suormala
T
T
Baumgartner
E R
ER
D017668:Age of Onset; D001710:Biotin / Q000627:therapeutic use*; D019735:Carbon-Carbon Ligases; D002658:Developmental Disabilities / Q000209:etiology; D018753:Diet, Protein-Restricted; D004829:Epilepsy, Generalized / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D008025:Ligases / Q000172:deficiency*; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications / Q000628:therapy; D010349:Patient Compliance; D014631:Valerates / Q000378:metabolism
D014631:Valerates; C004961:beta-hydroxyisovaleric acid; D001710:Biotin; D008025:Ligases; D019735:Carbon-Carbon Ligases; C021573:methylcrotonoyl-CoA carboxylase